Skip to main content
OpenTrials
Active, Not Recruiting

NCT Number: NCT06068348

Liquid Biopsy Collection Study

The purpose of this study is to develop a liquid biopsy approach for detection of circulating tumor cells (CTC) that could be used in place of the more invasive and potentially risky methods of tissue biopsy. The aims of the project are: (a) determine whether the Chaperonin-Containing TCP-1 (CCT) chaperonin can used to identify rare cancer cells in blood, and (b) establish whether the cancer cells detected using the CCT chaperonin for identification have invasive or metastatic potential.

Active, Not Recruiting

This study is active but is not currently recruiting participants.

Key information

Conditions

Chaperonin-Containing TCP-1 CCT CTC Circulating Tumor Cells Neoplasm Metastasis Neoplasms Neoplastic Cells, Circulating Neoplastic Processes Pathologic Processes Pathological Conditions, Signs and Symptoms

Age range

18 year–80 year

Sex eligibility

All sexes

Study type

Observational

Primary location

University of Central Florida

Orlando, Florida, 32816, United States

Who can participate

Healthy volunteers accepted: Yes

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Male or female
  • Age greater than or equal to 18 and less than or equal to 80 years.

Exclusion criteria

  • Adults unable to give informed consent
  • Individuals who are not yet adults (infants, children, teenagers; under the age of 18)
  • Individuals who weigh less than 110 lbs (as standard clinically advised to not give blood)
  • Pregnant women (due to hormonal changes in blood)
  • Prisoners
  • Persons reporting a current microbial (bacterial, viral, or fungal) infections
  • Persons reporting that they are current taking antibiotic medications
  • Persons with body temperatures above 99oF (indicating a fever)

Treatment and study plan

Primary outcomes

  1. To determine if the biomarker, Chaperonin-Containing TCP-1 (CCT), can be used to detect circulating tumor cells (CTC) in blood.

    Time frame: 3 years

Secondary outcomes

  1. To determine if the CCT chaperonin can provide information on the metastatic potential of CTC.

    Time frame: 3 years

Sponsors and collaborators

Lead sponsor

University of Central Florida

Other

Registry information

Official study title

Collection of Human Blood for Development of Liquid Biopsy Assay

Important dates

Study start
2021
Primary completion
2023
Study completion
2025
First posted
Oct 5, 2023
Registry last updated
Dec 6, 2024

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.